vs
豪洛捷（HOLX）与瑞思迈（RMD）财务数据对比。点击上方公司名可切换其他公司
瑞思迈的季度营收约是豪洛捷的1.4倍（$1.4B vs $1.0B），瑞思迈净利率更高（27.6% vs 17.1%，领先10.5%），瑞思迈同比增速更快（11.0% vs 2.5%），过去两年瑞思迈的营收复合增速更高（7.9% vs 1.5%）
豪洛捷是一家总部位于美国的医疗科技企业，核心业务聚焦女性健康领域，旗下产品涵盖诊断、外科手术及医学影像类专业医疗设备，为全球各地的医疗场景提供优质技术与产品支持。
瑞思迈是一家起源于澳大利亚、总部位于美国加利福尼亚州圣迭戈的医疗设备企业，主打可接入云端的呼吸类医疗设备，用于治疗睡眠呼吸暂停、慢性阻塞性肺病等呼吸道疾病，新冠疫情期间曾大量生产呼吸机等设备助力患者救治。
HOLX vs RMD — 直观对比
营收规模更大
RMD
是对方的1.4倍
$1.0B
营收增速更快
RMD
高出8.4%
2.5%
净利率更高
RMD
高出10.5%
17.1%
两年增速更快
RMD
近两年复合增速
1.5%
损益表 — Q1 FY2026 vs Q4 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $1.4B |
| 净利润 | $179.1M | $392.6M |
| 毛利率 | 56.0% | 61.8% |
| 营业利润率 | 22.6% | 34.6% |
| 净利率 | 17.1% | 27.6% |
| 营收同比 | 2.5% | 11.0% |
| 净利润同比 | -10.9% | 13.9% |
| 每股收益（稀释后） | $0.79 | $2.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HOLXRMD
| Q2 26 | — | $1.4B | ||
| Q4 25 | $1.0B | $1.4B | ||
| Q3 25 | $1.0B | $1.3B | ||
| Q2 25 | $1.0B | $1.3B | ||
| Q1 25 | $1.0B | $1.3B | ||
| Q4 24 | $1.0B | $1.3B | ||
| Q3 24 | $988.0M | $1.2B | ||
| Q2 24 | $1.0B | $1.2B |
净利润HOLXRMD
| Q2 26 | — | $392.6M | ||
| Q4 25 | $179.1M | $392.6M | ||
| Q3 25 | $187.2M | $348.5M | ||
| Q2 25 | $194.9M | $379.7M | ||
| Q1 25 | $-17.4M | $365.0M | ||
| Q4 24 | $201.0M | $344.6M | ||
| Q3 24 | $178.6M | $311.4M | ||
| Q2 24 | $194.5M | $292.2M |
毛利率HOLXRMD
| Q2 26 | — | 61.8% | ||
| Q4 25 | 56.0% | 61.8% | ||
| Q3 25 | 55.6% | 61.5% | ||
| Q2 25 | 56.3% | 60.8% | ||
| Q1 25 | 37.5% | 59.3% | ||
| Q4 24 | 56.8% | 58.6% | ||
| Q3 24 | 56.4% | 58.6% | ||
| Q2 24 | 55.4% | 58.5% |
营业利润率HOLXRMD
| Q2 26 | — | 34.6% | ||
| Q4 25 | 22.6% | 34.6% | ||
| Q3 25 | 22.6% | 33.4% | ||
| Q2 25 | 24.9% | 33.7% | ||
| Q1 25 | -0.7% | 33.0% | ||
| Q4 24 | 22.5% | 32.5% | ||
| Q3 24 | 23.3% | 31.6% | ||
| Q2 24 | 24.1% | 31.2% |
净利率HOLXRMD
| Q2 26 | — | 27.6% | ||
| Q4 25 | 17.1% | 27.6% | ||
| Q3 25 | 17.8% | 26.1% | ||
| Q2 25 | 19.0% | 28.2% | ||
| Q1 25 | -1.7% | 28.3% | ||
| Q4 24 | 19.7% | 26.9% | ||
| Q3 24 | 18.1% | 25.4% | ||
| Q2 24 | 19.2% | 23.9% |
每股收益（稀释后）HOLXRMD
| Q2 26 | — | $2.68 | ||
| Q4 25 | $0.79 | $2.68 | ||
| Q3 25 | $0.84 | $2.37 | ||
| Q2 25 | $0.86 | $2.58 | ||
| Q1 25 | $-0.08 | $2.48 | ||
| Q4 24 | $0.87 | $2.34 | ||
| Q3 24 | $0.75 | $2.11 | ||
| Q2 24 | $0.82 | $1.97 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.4B | $1.4B |
| 总债务越低越好 | $2.5B | $663.8M |
| 股东权益账面价值 | $5.2B | $6.3B |
| 总资产 | $9.2B | $8.5B |
| 负债/权益比越低杠杆越低 | 0.48× | 0.11× |
8季度趋势，按日历期对齐
现金及短期投资HOLXRMD
| Q2 26 | — | $1.4B | ||
| Q4 25 | $2.4B | $1.4B | ||
| Q3 25 | $2.2B | $1.4B | ||
| Q2 25 | $1.9B | $1.2B | ||
| Q1 25 | $1.6B | $932.7M | ||
| Q4 24 | $2.0B | $521.9M | ||
| Q3 24 | $2.3B | $426.4M | ||
| Q2 24 | $2.4B | $238.4M |
总债务HOLXRMD
| Q2 26 | — | $663.8M | ||
| Q4 25 | $2.5B | $403.9M | ||
| Q3 25 | $2.5B | $408.7M | ||
| Q2 25 | $2.5B | $658.4M | ||
| Q1 25 | $2.5B | $663.1M | ||
| Q4 24 | $2.5B | $662.9M | ||
| Q3 24 | $2.5B | $667.6M | ||
| Q2 24 | $2.5B | $697.3M |
股东权益HOLXRMD
| Q2 26 | — | $6.3B | ||
| Q4 25 | $5.2B | $6.3B | ||
| Q3 25 | $5.0B | $6.1B | ||
| Q2 25 | $4.8B | $6.0B | ||
| Q1 25 | $4.6B | $5.5B | ||
| Q4 24 | $4.8B | $5.3B | ||
| Q3 24 | $5.1B | $5.2B | ||
| Q2 24 | $5.0B | $4.9B |
总资产HOLXRMD
| Q2 26 | — | $8.5B | ||
| Q4 25 | $9.2B | $8.5B | ||
| Q3 25 | $9.0B | $8.3B | ||
| Q2 25 | $8.8B | $8.2B | ||
| Q1 25 | $8.5B | $7.6B | ||
| Q4 24 | $8.7B | $7.1B | ||
| Q3 24 | $9.2B | $7.2B | ||
| Q2 24 | $8.9B | $6.9B |
负债/权益比HOLXRMD
| Q2 26 | — | 0.11× | ||
| Q4 25 | 0.48× | 0.06× | ||
| Q3 25 | 0.50× | 0.07× | ||
| Q2 25 | 0.52× | 0.11× | ||
| Q1 25 | 0.55× | 0.12× | ||
| Q4 24 | 0.53× | 0.13× | ||
| Q3 24 | 0.49× | 0.13× | ||
| Q2 24 | 0.51× | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $229.9M | — |
| 自由现金流经营现金流 - 资本支出 | $215.2M | — |
| 自由现金流率自由现金流/营收 | 20.5% | — |
| 资本支出强度资本支出/营收 | 1.4% | — |
| 现金转化率经营现金流/净利润 | 1.28× | — |
| 过去12个月自由现金流最近4个季度 | $1.0B | — |
8季度趋势，按日历期对齐
经营现金流HOLXRMD
| Q2 26 | — | — | ||
| Q4 25 | $229.9M | $339.7M | ||
| Q3 25 | $355.1M | $457.3M | ||
| Q2 25 | $343.3M | $538.8M | ||
| Q1 25 | $169.4M | $578.7M | ||
| Q4 24 | $189.3M | $308.6M | ||
| Q3 24 | $367.0M | $325.5M | ||
| Q2 24 | $405.8M | $440.1M |
自由现金流HOLXRMD
| Q2 26 | — | — | ||
| Q4 25 | $215.2M | $311.2M | ||
| Q3 25 | $341.4M | $414.4M | ||
| Q2 25 | $330.5M | $508.2M | ||
| Q1 25 | $153.9M | $557.9M | ||
| Q4 24 | $172.5M | $288.0M | ||
| Q3 24 | $350.6M | $307.7M | ||
| Q2 24 | $385.3M | $415.2M |
自由现金流率HOLXRMD
| Q2 26 | — | — | ||
| Q4 25 | 20.5% | 21.9% | ||
| Q3 25 | 32.5% | 31.0% | ||
| Q2 25 | 32.3% | 37.7% | ||
| Q1 25 | 15.3% | 43.2% | ||
| Q4 24 | 16.9% | 22.5% | ||
| Q3 24 | 35.5% | 25.1% | ||
| Q2 24 | 38.1% | 33.9% |
资本支出强度HOLXRMD
| Q2 26 | — | — | ||
| Q4 25 | 1.4% | 2.0% | ||
| Q3 25 | 1.3% | 3.2% | ||
| Q2 25 | 1.3% | 2.3% | ||
| Q1 25 | 1.5% | 1.6% | ||
| Q4 24 | 1.6% | 1.6% | ||
| Q3 24 | 1.7% | 1.5% | ||
| Q2 24 | 2.0% | 2.0% |
现金转化率HOLXRMD
| Q2 26 | — | — | ||
| Q4 25 | 1.28× | 0.87× | ||
| Q3 25 | 1.90× | 1.31× | ||
| Q2 25 | 1.76× | 1.42× | ||
| Q1 25 | — | 1.59× | ||
| Q4 24 | 0.94× | 0.90× | ||
| Q3 24 | 2.05× | 1.05× | ||
| Q2 24 | 2.09× | 1.51× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
RMD
暂无分部数据
